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Introduction
The Neurofibromatosis type I (NF1), or von Recklinghausen disease, is a hereditary multisystem disorder that primarily involves the skin and nervous system. Without special predilection for race or sex and with an incidence of 1:3500 live birth, neurofibromatosis type 1 (NF1) is the most common form of autosomal dominant phakomatoses [1] . NF1 has 100% penetrance but wide phenotypic variability with great variation in the clinical manifestation of the disease, both interfamiliar and intra-familiar [2, 3] . The NF1 gene is located on chromosome 17q11.2 and the protein product, termed neurofibromin, acts as a tumour suppressor [4, 5] Because affected individuals have approximately 5-15% higher risk of tumour formation than the general population [6] , this disorder is classified as inherited cancer syndrome. This event is considered the most common cause of death, with life expectancy reduced by 10-15 years [7] .
Clinical features and diagnosis
The principal clinical manifestations of NF1 are cafe au lait spots (CALS), neurofibromas, skin-fold freckling, iris hamartomas (Lisch nodules) and characteristic skeletal anomalies [8] . In addition to these features, affected individuals can develop a less penetrant variety of additional abnormalities of the skin, eyes, nervous system (e.g., epilepsy, macrocephaly, mental retardation, learning disabilities), endocrine organs (e.g., sexual precocity), bones and blood vessels [9] ( Table 1) . It is also considered to be a progressive condition with diverse complications that occur during the disease. CALS, pseudarthrosis and externally visible plexiform neurofibromas usually appear over the course of infancy. In the first decade of life can arise freckling, optic gliomas and severe scoliosis. Instead, cutaneous neurofibromas and iris Lisch nodules are frequently apparent during the second decade [10] .
The diagnosis is based on clinical diagnostic criteria proposed by the NIH Consensus Development Conference of Bethesda ( Table 2 ). The disorder is generally recognized during infancy, when cutaneous manifestations are evident. To confirm the diagnosis in affected individuals who perform the diagnostic criteria for NF1, different diagnostic tests are disposables. Recent mutation testing allows the recognition of pathogenic mutations in more than 95% of patient, using a combination of optimised protein truncation testing, fluorescent in situ hybridisation, direct sequencing, Southern blot analysis, and cytogenetic analysis [11] . Foetal DNA analysis extracted from chorionic villous sampling or amniocentesis can detect pathogenic mutations in prenatal age, though their use is limited because of the inability to predict disease severity.
Genetic and tumorigenesis
The NF1 gene was assigned to chromosome 17q11.2 by positional cloning. The NF1 gene is extremely large spanning over 350 kb of genomic DNA with 60 exons [12] . The NF1 gene product, called neurofibromin, is a ubiquitous protein expressed mainly in neurons, Schwann cells, astrocytes, oligodendrocytes and leukocytes [13, 14] . Different human mutations across the entire NF1 gene have been identified from various studies [15] but a clear correlation between specific mutation and clinical presentations has not been shown. Neurofibromin, in correspondence of exons 20-27a, has a region of homology with p120-GAP that is a GTPase-activing protein (GAP) for the ras family of proto-oncogenes [16] . This 'GAP related domain'(GRD) accelerates the GTP-hydrolysis activity and thus deregulates p21-ras. Ras is a 21-kDa transmembrane protein that has a cardinal role in the regulation of cellular growth and differentiation. When GTP is hydrolyzed to GDP, ras is inactived leading to uncontrolled cell proliferation escaping from apoptosis [17] . Beside the Ras pathway, NF1 may also function upstream of PKA to modulate cell proliferation in the cAMP pathway.
The activating mutations in ras seem to implicate malignant transformations [18] . Consistent with Kudson's "two hit" model of tumorigenesis, the deletions of the germline and the presence of somatic punctiform mutations in the gene NF1 cause inactivity of both copies of the gene [19] and loss of its "tumor soppressor" function. This leads NF1 individuals to develop a variety of malignancies as well as benign tumors [20] . The finding of loss of heterozygosity (LOH) at the NF1 locus in tumors of NF1 patients underlines the tumor suppressor function of the gene. Also in sporadic cancers is observed somatic inactivation of the second NF1 allele. Therefore, the development of malignancies in NF1-affected patients of additional genetic abnormalities that determine the inactivation of PTEN, TP53, CDKN2A, or the amplification of platelet-derived growth factor receptor or epidermal growth factor receptor [21] [22] [23] . Furthermore, as multiple primary tumors are associated with this disorder, NF1-related tumor susceptibility seems influenced from further modifying genes and epigenetic phenomena.
Tumours
Tumours are among the most common complications and represent the main cause of morbidity and mortality. As in other tumor-predisposing syndromes, NF1- In order to make diagnosis, at least 2 major criteria are required. 
Neurofibromas and malignant peripheral nerve sheath tumours
Neurofibromas are the most common tumour in NF1 and can be classified into three subtypes, dermal, subcutaneous and plexiforme. Dermal and subcutaneous types are typically apparent during puberty and the number increases progressively with age and especially in pregnancy. They comprise all supporting elements of the nerve fibers, including Schwann cells, fibroblasts, perineurial cells, axons, blood vessels and mast cells surrounded from an extracellular matrix [28] . Some are purplish depressions in the skin whereas others are pedunculated lesions. Plexiform neurofibromas are considered to be pathognomonic lesions of the disease and occur in about 30% of affected individuals. Plexiform neurofibromas have similar histological patterns to cutaneous neurofibromas but differ in greater vascularization and increased extracellular matrix. They can arise in all organs involving superficial skin or be completely internal. Many are asymptomatic [29] and the clinical symptoms depend on size, location, and timing of growth that is unpredictable [30] . Large facial plexiform neurofibromas can lead to the loss of visual acuity whereas neurofibromas involving the sacral plexus can cause compression of the ureters, rectum and uterus. Thoracic neurofibromas arising from the chest wall or from the mediastinum were also observed. Dermal neurofibromas are mainly benign, but in 10% of cases it can give rise to malignant peripheral nerve sheath tumours (MPNST) [31, 32] The risk of MPNST developing in NF1-affected individuals has been estimated at 8% to 13%, as compared with 0.001% in the general population [33] . From the other side, different studies have reported wide incidence rates of NF1 in MPNST series with a range from 15% to 70% [34] . NF1-associated MPNST arise at significantly earlier age (the mean age is 26) than in sporadic MPNSTs (the mean age is 62), and for NF1-associated MPNSTs the fiveyear survival rate is only 21%, compared to 42% for sporadic MPNSTs. Clinical manifestations are extremely variable and can lead devastating complications. These tumors can cause neurological deficiencies or severe pain related to their rapid growth and often leads to metastasis to the lungs. MPNSTs are commonly located in correspondence to the proximal extremities growing along adjacent nerves or infiltrating adjoining soft tissue.
Macroscopically, they are firm tumours with foci of haemorrhage or necrosis and can present ill-defined margins or be pseudo-encapsulated. These tumors are lacking in standard histologic criteria and hence, difficult to diagnose. These tumours may have different histological features containing malignant areas of divergent mesenchymal differentiation. Malignant peripheral nerve that sheaths the tumour with rhabdomyosarcomatous differentiation is also known as malignant triton tumour (MTT) [35] . Malignant triton tumours have more aggressive behaviours than classic MPNSTs and the diagnosis of MTT confer a worse prognosis.
The treatment consists in surgical excision with tumour-free margins associated with chemotherapy (ifosfamide and doxorubicin), but survival beyond a year is uncommon.
Both NF1-associated and sporadic MPNSTs show the loss or mutation of NF-1 gene expression [36] A large variety of human mutations has been identified such as total deletion of the gene, frame-shift mutation, in-frame deletion, missense mutation [37] and the risk of developing MPNST seems to depend on the type of mutation. Patients with small truncating NF-1 mutations have generally lower risk than patients with microdeletions including the entire NF-1 gene [38, 39] . Therefore, tumour development require additional genetic events that inactivate key cell cycle regulators, including p16, p53 and other regulating genes such as CDKN1B and CDKN2A [40] . The low incidence of MPNSTs in clinical practice can be correlated to the necessity of two or more mutations for development of this tumor.
Optic pathway gliomas
Optic gliomas are the second most common tumour in NF1, approximately observed in about 15% of NF1. They can be found at any age, but generally occurs by the 6 th year of age [41, 42] , after which it presents as a rare complication. These tumours frequently arise along the optic nerves and chiasm, but can also be detected in the hypothalamus or brainstem [43] . These tumors are almost classified as low grade astrocytomas and they show a benign or slowly progressive behavior. In the majority of the cases, the neoplasm has an indolent course and only in approximately one third of the cases causes clinical symptoms such as visual acuity loss, decreased color vision, abnormal papillary function, proptosis and endocrinological abnormalities (sign of hypothalamic suffering). The natural history of NF1-associated optic pathway gliomas is completely unpredictable but generally these tumors recognize a more favourable prognosis [44] than those arising in patients without NF1. Periodic ophthalmological examinations [45] and neuro-radiological monitoring orders define the start of therapy and subsequent clinical evolution for preventing of irreversible symptoms. Treatment can include combined chemotherapy with Carboplatin and Vincristine which represents the first choice-treatment; surgery and radiotherapy are feasible only in selected cases (resecability and age of patients) and they are performed only when signs of clinical and/ or radiological progression are detected.
Several studies support the function of neurofibromin as a growth regulator in astrocytes. Loss of neurofibromin in microglias and neurons seems to determine the activation of the KRAS isoform in astrocytes and of the mTOR-S6 kinase pathway leading to increase of cell proliferation [46] and contributing to optic glioma tumorigenesis [47] . Furthermore, additional genetic mutations should influence the pathogenesis of the minority of NF1-associated optic/hypothalamic pathway that present clinical progression.
Non-neurogenic sarcomas
After malignant peripheral nerve sheath tumor, rhabdomyosarcoma (RMS) is the most common type of non-neurogenic sarcoma in NF1. In affected patient the prevalence is 20 times higher than in the general population [48] . In the Italian pediatric population of RMS seen at AIEOP centers, it is an estimated prevalence of NF1 of 1%. Resembled that of the general RMS population, NF1-associated RMS present various peculiar characteristics: a genitourinary location (other locations include the orbit, trunk, and head and neck region) [49] , appearance in early age (the mean age is 3 years old) and embryonal histotypes (60-70% of all RMS). Often the diagnosis has been set when the tumor is already advanced, but these tumors have generally a good response to chemotherapic treatment with outcomes comparable to that of sporadic RMS. The genetic basis for RMS in NF1 is not well understood. The pand, probably, the p53 tumor suppressor gene is involved [50] .
Other tumors
Young patients with NF1 have an increased risk of development malignant myeloid disorders, such as juvenile chronic myelogenous leukaemia (JCML), acute myeloid leukaemia (AML), and monosomy 7 syndrome [51] . The genetic disruption of both copies of the NF1 gene has been detected from DNA extracted from the bone marrow of affected children with NF1 and myeloproliferative syndrome [52] . Based on these findings, the results are reasonable that the NF1 gene could have a direct effect on the genesis of myelogenous leukaemia. The predominance of myelogenous leukaemia in NF1 patients suggests a role of the NF1 gene in activating the ras gene: ras gene mutations have been reported in some myelogenous leukemia and not in ALL. The inactivation of p53 alleles might contribute to leukemogenesis in the patient with NF1.
NF1 patients are also predisposed to develop other malignancies. These include pheochromocytomas, duodenal carcinoid, hepatoblastoma, somatostatinoma and parathyroid adenoma. As not all NF1 affected individuals develop malignancies, they provide evidence that various genetic and non-genetic factors modulate NF1-associated tumor susceptibility.
Conclusions
NF1 is considered as one of the most frequent hereditary syndromes. It is a multisystem and progressive disorder that affects different organs, including the skin, eyes, central nervous system, peripheral nervous system, and the skeletal, cardiovascular, gastroenteric and endocrine systems. Affected individuals have a propensity for developing both benign and malignant tumors. The malignancies are among the most common complications and represent the main cause of morbidity and mortality. Additional elucidation of molecular pathogenesis of NF1 provide hope to develop new therapies aimed at preventing tumour development.
